165 related articles for article (PubMed ID: 37951919)
21. Clinical impact of a cytological screening system using cyclin D1 immunostaining and genomic analysis for the diagnosis of thyroid nodules.
Teshima M; Tokita K; Ryo E; Matsumoto F; Kondo M; Ikegami Y; Shinomiya H; Otsuki N; Hiraoka N; Nibu KI; Yoshimoto S; Mori T
BMC Cancer; 2019 Mar; 19(1):245. PubMed ID: 30885146
[TBL] [Abstract][Full Text] [Related]
22. Unique patterns of tumor growth related with the risk of lymph node metastasis in papillary thyroid carcinoma.
Jung CK; Kang YG; Bae JS; Lim DJ; Choi YJ; Lee KY
Mod Pathol; 2010 Sep; 23(9):1201-8. PubMed ID: 20543822
[TBL] [Abstract][Full Text] [Related]
23. CCNA1 gene as a potential diagnostic marker in papillary thyroid cancer.
da Silva RM; Santos JN; Uno M; Chammas R; Kulcsar MAV; Sant'Anna LB; Canevari RA
Acta Histochem; 2020 Dec; 122(8):151635. PubMed ID: 33007517
[TBL] [Abstract][Full Text] [Related]
24. [Clinical analysis of lymphocytic thyroiditis coexistent with papillary thyroid carcinoma].
Wang SX; She ZQ; An CM; Zhang XW; Li ZJ; Tang PZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Apr; 51(4):277-81. PubMed ID: 27095720
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic and prognostic value of tumor-infiltrating B cells in lymph node metastases of papillary thyroid carcinoma.
Yang Z; Yin L; Zeng Y; Li Y; Chen H; Yin S; Zhang F; Yang W
Virchows Arch; 2021 Nov; 479(5):947-959. PubMed ID: 34148127
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-451 as a prognostic marker for diagnosis and lymph node metastasis of papillary thyroid carcinoma.
Zhang M; Wu W; Gao M; Fei Z
Cancer Biomark; 2017 Jul; 19(4):437-445. PubMed ID: 28582849
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.
Park YJ; Kwak SH; Kim DC; Kim H; Choe G; Park DJ; Jang HC; Park SH; Cho BY; Park SY
J Korean Med Sci; 2007 Aug; 22(4):621-8. PubMed ID: 17728499
[TBL] [Abstract][Full Text] [Related]
28. Expression of HBME-1 and CD56 in follicular variant of papillary carcinoma in children: An immunohistochemical study and their diagnostic utility.
Skaria PE; Ahmed AA; Yin H; Nicol K; Reid KJ; Singh V
Pathol Res Pract; 2019 May; 215(5):880-884. PubMed ID: 30711197
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19.
Murtezaoglu AR; Gucer H
Pol J Pathol; 2017; 68(1):1-10. PubMed ID: 28547974
[TBL] [Abstract][Full Text] [Related]
30. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.
Saleh HA; Jin B; Barnwell J; Alzohaili O
Diagn Pathol; 2010 Jan; 5():9. PubMed ID: 20181018
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical levels of matrix metalloproteinase-2 and CD44 variant 6 protein in the diagnosis and lateral cervical lymph node metastasis of papillary thyroid carcinoma.
Wu G; Zhou Y; Li T; Guo J; Zhou Z
J Int Med Res; 2013 Jun; 41(3):816-24. PubMed ID: 23685894
[TBL] [Abstract][Full Text] [Related]
32. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases.
Yu XM; Lo CY; Chan WF; Lam KY; Leung P; Luk JM
Clin Cancer Res; 2005 Nov; 11(22):8063-9. PubMed ID: 16299237
[TBL] [Abstract][Full Text] [Related]
33. Expression of matrix metalloproteinase-2 and its tissue inhibitor-2 in fetal and neoplastic thyroid tissue and their significance as diagnostic and prognostic markers in papillary carcinoma.
Marečko I; Cvejić D; Tatić S; Dragutinović V; Paunović I; Savin S
Cancer Biomark; 2011-2012; 11(1):49-58. PubMed ID: 22820140
[TBL] [Abstract][Full Text] [Related]
34. Altered expression of cyclins and cell cycle inhibitors in papillary thyroid cancer: prognostic implications.
Pickett CA; Agoff SN; Widman TJ; Bronner MP
Thyroid; 2005 May; 15(5):461-73. PubMed ID: 15929668
[TBL] [Abstract][Full Text] [Related]
35. Peroxisome proliferator activated receptor gamma immunohistochemical expression in human papillary thyroid carcinoma tissues. Possible relationship to lymph node metastasis.
Galusca B; Dumollard JM; Chambonniere ML; Germain N; Prades JM; Péoc'h M; Estour B
Anticancer Res; 2004; 24(3b):1993-7. PubMed ID: 15274390
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical study of papillary thyroid carcinoma and possible papillary thyroid carcinoma-related benign thyroid nodules.
Mai KT; Ford JC; Yazdi HM; Perkins DG; Commons AS
Pathol Res Pract; 2000; 196(8):533-40. PubMed ID: 10982016
[TBL] [Abstract][Full Text] [Related]
37. Strong expression of HBME-1 associates with high-risk clinicopathological factors of papillary thyroid carcinoma.
Dencic TM; Savin SB; Selemetjev SA; Paskas SD; Zivaljevic VR; Bozic VD; Cvejic DS
Pathol Oncol Res; 2015 Jul; 21(3):735-42. PubMed ID: 25577274
[TBL] [Abstract][Full Text] [Related]
38. [Usefulness of the immunohistochemical analysis of several molecular markers in the characterization of papillary thyroid carcinoma with initial lymph node metastasis].
Zafón C; Castellví J; Obiols G
Endocrinol Nutr; 2010 Apr; 57(4):165-9. PubMed ID: 20403734
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic Value of TROP2 Expression in Papillary Thyroid Carcinoma.
Saffar H; Jahanbin B; Ameli F; Farhang F; Tavangar SM; Saffar H
Appl Immunohistochem Mol Morphol; 2021 Mar; 29(3):218-222. PubMed ID: 33264108
[TBL] [Abstract][Full Text] [Related]
40. [The expression and significance of trefoil factor 3 and SDF-1/CXCR4 biological axis in papillary thyroid carcinoma].
Xue G; Huang J; Zhang H; Zhang W; Wu J; Shang X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Jan; 28(2):108-12. PubMed ID: 24738314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
